Trial Profile
A Controlled, Prospective, Blinded, Randomized, Single-Center, Study of YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs YSPSL (Primary)
- Indications Reperfusion injury
- Focus Adverse reactions
- Sponsors Ys Therapeutics
- 04 Jun 2014 New trial record